{"title":"预防和治疗偏头痛","authors":"S. Chaplin","doi":"10.1002/psb.2044","DOIUrl":null,"url":null,"abstract":"Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rimegepant for the prevention and treatment of migraine\",\"authors\":\"S. Chaplin\",\"doi\":\"10.1002/psb.2044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2044\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rimegepant for the prevention and treatment of migraine
Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
